Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia

Neuropsychopharmacology

Volumn 35, Issue 12, 2010, Pages 2462-2478

  Bitanihirwe, Byron Ky ^a   Peleg Raibstein, Daria ^a   Mouttet, Forouhar ^a   Feldon, Joram ^a   Meyer, Urs ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

anhedonia; behavioral cognitive flexibility; dopamine; glutamate; prefrontal cortex; social interaction

Indexed keywords

4 AMINOBUTYRIC ACID; APOMORPHINE; ASPARTIC ACID; DOPAMINE; GLUTAMIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; SEROTONIN; TAURINE;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; IMMUNOREACTIVITY; LATENT INHIBITION; LOCOMOTION; MALE; MOUSE; NEGATIVE SYNDROME; NEUROCHEMISTRY; NONHUMAN; PHENOTYPE; PREFRONTAL CORTEX; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; PSYCHOLOGIC TEST; SCHIZOPHRENIA; SEX TRANSFORMATION; SOCIAL INTERACTION;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; GLYCINE; HIPPOCAMPUS; MALE; MICE; MICE, INBRED C57BL; POLY I-C; PREFRONTAL CORTEX; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX CHARACTERISTICS;

EID: 77957986357     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.129     Document Type: Article

References (93)

1. Aleman A, Kahn RS, Selten JP (2003). Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry 60: 565-571.
2. Arguello PA, Gogos JA (2006). Modeling madness in mice: one piece at a time. Neuron 52: 179-196.
3. Berridge KC, Robinson TE (1998). What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28: 309-369.
4. Bitanihirwe BK, Weber L, Feldon J, Meyer U (2010). Cognitive impairment following prenatal immune challenge in mice correlates with prefrontal cortical AKT1 deficiency. Int J Neuro-psychopharmacol in press (Epub ahead of print [PMID: 20219156]).
5. Blanchard JJ, Cohen AS (2006). The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 32: 238-245.
6. Brown AS (2006). Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 32: 200-202.
7. Brown AS, Derkits EJ (2010). Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 167: 261-280.
8. Brown AS, Susser ES (2008). Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr Bull 34: 1054-1063.
9. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP et al (2007). The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164: 1593-1602.
10. Cabib S, D'Amato FR, Puglisi-Allegra S, Maestripieri D (2000). Behavioral and mesocorticolimbic dopamine responses to non aggressive social interactions depend on previous social experiences and on the opponent's sex. Behav Brain Res 112: 13-22.
11. Cabib S, Puglisi-Allegra S (1985). Different effects of apomorphine on climbing behavior and locomotor activity in three strains of mice. Pharmacol Biochem Behav 23: 555-557.
12. Cagniard B, Balsam PD, Brunner D, Zhuang X (2006). Mice with chronically elevated dopamine exhibit enhanced motivation, but not learning, for a food reward. Neuropsychopharmacology 31: 1362-1370.
13. Clancy B, Darlington RB, Finlay BL (2001). Translating developmental time across mammalian species. Neuroscience 105: 7-17.
14. Clancy B, Finlay BL, Darlington RB, Anand KJ (2007). Extrapolating brain development from experimental species to humans. Neurotoxicology 28: 931-937.
15. Cohen E, Sereni N, Kaplan O, Weizman A, Kikinzon L, Weiner I et al (2004). The relation between latent inhibition and symptom-types in young schizophrenics. Behav Brain Res 149: 113-122.
16. Crawley JN (2007). Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 17: 448-459.
17. Crider A (1997). Perseveration in schizophrenia. Schizophr Bull 23: 63-74.
18. Crow TJ (1980). Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137: 383-386.
19. Cryan JF, Mombereau C (2004). In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9: 326-357.
20. Dalley JW, Cardinal RN, Robbins TW (2004). Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28: 771-784.
21. Davis KL, Kahn RS, Ko G, Davidson M (1991). Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486.
22. Ellenbroek BA, Cools AR (2000). Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11: 223-233.
23. Errico F, Nisticò R, Palma G, Federici M, Affuso A, Brilli E et al (2008). Increased levels of D-aspartate in the hippocampus enhance LTP but do not facilitate cognitive flexibility. Mol Cell Neurosci 37: 236-246.
24. Fatemi SH (2005). Neuropsychiatric Disorders and Infection. Martin Dunitz-Taylor & Francis Group: London, UK.
25. Fatemi SH, Folsom TD (2009). The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35: 528-548.
26. Fatemi SH, Reutiman TJ, Folsom TD, Huang H, Oishi K, Mori S et al (2008). Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 99: 56-70.
27. Fernandez Espejo E (2003). Prefrontocortical dopamine loss in rats delays long-term extinction of contextual conditioned fear, and reduces social interaction without affecting short-term social interaction memory. Neuropsychopharmacology 28: 490-498.
28. Flor-Henry P (1990). Influence of gender in schizophrenia as related to other psychopathological syndromes. Schizophr Bull 16: 211-227.
29. Foussias G, Remington G (2010). Negative symptoms in schizophrenia: Avolition and Occam's razor. Schizophr Bull 36: 359-369.
30. Gaisler-Salomon I, Diamant L, Rubin C, Weiner I (2008). Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology 196: 255-267.
31. Gaisler-Salomon I, Weiner I (2003). Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol. Psychophar-macology 166: 333-342.
32. Goff DC, Coyle JT (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158: 1367-1377.
33. Hava G, Vered L, Yael M, Mordechai H, Mahoud H (2006). Alterations in behavior in adult offspring mice following maternal inflammation during pregnancy. Dev Psychobiol 48: 162-168.
34. Hayward MD, Schaich-Borg A, Pintar JE, Low MJ (2006). Differential involvement of endogenous opioids in sucrose consumption and food reinforcement. Pharmacol Biochem Behav 85: 601-611.
35. Hirschowitz J, Zemlan FP, Hitzemann RJ, Fleischmann RL, Garver DL (1986). Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems. Biol Psychiatry 21: 445-454.
36. Horan WP, Blanchard JJ, Clark LA, Green MF (2008). Affective traits in schizophrenia and schizotypy. Schizophr Bull 34: 856-874.
37. Juckel G, Sass L, Heinz A (2003). Anhedonia, self-experience in schizophrenia, and implications for treatment. Pharmacopsy-chiatry 36: S176-S180.
38. Kimura M, Toth LA, Agostini H, Cady AB, Majde JA, Krueger JM (1994). Comparison of acute phase responses induced in rabbits by lipopolysaccharide and double-stranded RNA. Am J Physiol 267: R1596-R1605.
39. Knable MB, Weinberger DR (1997). Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 11: 123-131.
40. Koenig JI, Kirkpatrick B, Lee P (2002). Glucocorticoid hormones and early brain development in schizophrenia. Neuropsycho-pharmacology 27: 309-318.
41. Li Q, Cheung C, Wei R, Hui ES, Feldon J, Meyer U et al (2009). Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant to schizophrenia: evidence from MRI in a mouse model. PLoS One 4: e6354.
42. Lipina T, Labrie V, Weiner I, Roder J (2005). Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology 179: 54-67.
43. Lubow RE (2005). Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull 31: 139-153.
44. McGlashan TH, Fenton WS (1992). The positive-negative distinction in schizophrenia. Review of natural history validators. Arch Gen Psychiatry 49: 63-72.
45. Meltzer HY, Kolakowska T, Fang VS, Fogg L, Robertson A, Lewine R et al (1984). Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. Arch Gen Psychiatry 41: 512-519.
46. Meyer U, Feldon J (2009). Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 204: 322-334.
47. Meyer U, Feldon J (2010). Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 90: 285-326.
48. Meyer U, Feldon J, Fatemi SH (2009a). In-vivo rodent models for the experimental investigation of prenatal immune activation effects in neurodevelopmental brain disorders. Neurosci Biobe-hav Rev 33: 1061-1079.
49. Meyer U, Feldon J, Schedlowski M, Yee BK (2005). Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29: 913-947.
50. Meyer U, Feldon J, Schedlowski M, Yee BK (2006a). Immunological stress at the maternal-foetal interface: a link between neurode-velopment and adult psychopathology. Brain Behav Immun 20: 378-388.
51. Meyer U, Feldon J, Yee BK (2009b). A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 35: 959-972.
52. Meyer U, Knuesel I, Nyffeler M, Feldon J (2010). Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis. Psychopharmacology 208: 531-543.
53. Meyer U, Murray PJ, Urwyler A, Yee BK, Schedlowski M, Feldon J (2008a). Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 13: 208-221.
54. Meyer U, Nyffeler M, Engler A, Urwyler A, Schedlowski M, Knuesel I et al (2006b). The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 26: 4752-4762.
55. Meyer U, Nyffeler M, Schwendener S, Knuesel I, Yee BK, Feldon J (2008b). Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. Neuropsychopharmacology 33: 441-456.
56. Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J (2008c). Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 22: 469-486.
57. Meyer U, Schwendener S, Feldon J, Yee BK (2006c). Prenatal and postnatal maternal contributions in the infection model of schizophrenia. Exp Brain Res 173: 243-257.
58. Meyer U, Yee BK, Feldon J (2007). The neurodevelopmental impact of prenatal infections at different times of pregnancy: the earlier the worse? Neuroscientist 13: 241-256.
59. Morrens M, Hulstijn W, Lewi PJ, De Hert M, Sabbe BG (2006). Stereotypy in schizophrenia. Schizophr Res 84: 397-404.
60. Ozawa K, Hashimoto K, Kishimoto T, Shimizu E, Ishikura H, Iyo M (2006). Immune activation during pregnancy in mice leads to dopaminergic hyperfunction and cognitive impairment in the offspring: a neurodevelopmental animal model of schizophrenia. Biol Psychiatry 59: 546-554.
61. Patterson PH (2007). Maternal effects on schizophrenia risk. Science 318: 576-577.
62. Patterson PH (2009). Immune involvement in schizophrenia and autism: etiology, pathology and animal models. Behav Brain Res 204: 313-321.
63. Peleg-Raibstein D, Knuesel I, Feldon J (2008). Amphetamine sensitization in rats as an animal model of schizophrenia. Behav Brain Res 191: 190-201.
64. Peleg-Raibstein D, Pezze MA, Ferger B, Zhang WN, Murphy CA, Feldon J et al (2005). Activation of dopaminergic neurotrans-mission in the medial prefrontal cortex by N-methyl-D-aspartate stimulation of the ventral hippocampus in rats. Neuroscience 132: 219-232.
65. Pothion S, Bizot JC, Trovero F, Belzung C (2004). Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res 155: 135-146.
66. Protais P, Costentin J, Schwartz JC (1976). Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 50: 1-6.
67. Rapoport JL, Addington AM, Frangou S, Psych MR (2005). The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10: 434-449.
68. Rascle C, Mazas O, Vaiva G, Tournant M, Raybois O, Goudemand M et al (2001). Clinical features of latent inhibition in schizophrenia. Schizophr Res 51: 149-161.
69. Remington G, Foussias G, Agid O (2010). Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 24: 9-20.
70. Roy MA, Maziade M, Labbé A, Mérette C (2001). Male gender is associated with deficit schizophrenia: a meta-analysis. Schizophr Res 47: 141-147.
71. Schooler C, Spohn HE (1982). Social dysfunction and treatment failure in schizophrenia. Schizophr Bull 8: 85-98.
72. Shi L, Fatemi SH, Sidwell RW, Patterson PH (2003). Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci 23: 297-302.
73. Singer P, Boison D, Möhler H, Feldon J, Yee BK (2009). Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability? Behav Neurosci 123: 1012-1027.
74. Slattery DA, Markou A, Cryan JF (2007). Evaluation of reward processes in an animal model of depression. Psychopharmacol-ogy 190: 555-568.
75. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH (2007). Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 27: 10695-10702.
76. Sullivan R, Wilson DA, Feldon J, Yee BK, Meyer U, Richter-Levin G et al (2006). The International Society for Developmental Psychobiology annual meeting symposium: impact of early life experiences on brain and behavioral development. Dev Psycho-biol 48: 583-602.
77. Susser E, St Clair D, He L (2008). Latent effects of prenatal malnutrition on adult health: the example of schizophrenia. Ann N Y Acad Sci 1136: 185-192.
78. Tamminga CA (2006). The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67(Suppl 9): 9-13.
79. Tirelli E, Witkin JM (1994). Transient hypersensitivity to apomorphine-induced gnawing after termination of acute effects of a single high dose of cocaine. Behav Pharmacol 5: 289-298.
80. Traynor TR, Majde JA, Bohnet SG, Krueger JM (2004). Intra-tracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections. Life Sci 74: 2563-2576.
81. Vuillermot S, Weber L, Feldon J, Meyer U (2010). A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopami-nergic development relevant to schizophrenia. J Neurosci 30: 1270-1287.
82. Watson CG, Kucala T, Angulski G, Vassar P (1987). The relationships of anhedonia and the process-reactive dimension to season of birth and infectious disease incidence in schizophrenia. J Nerv Ment Dis 175: 34-40.
83. Weinberger DR (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669.
84. Weiner I (1990). Neural substrates of latent inhibition: the switching model. Psychol Bull 108: 442-461.
85. Weiner I (2003). The 'two-headed' latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169: 257-297.
86. Weiner I, Arad M (2009). Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res 204: 369-386.
87. Winter C, Djodari-Irani A, Sohr R, Morgenstern R, Feldon J, Juckel G et al (2009). Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 12: 513-524.
88. Winter C, Reutiman TJ, Folsom TD, Sohr R, Wolf RJ, Juckel G et al (2008). Dopamine and serotonin levels following prenatal viral infection in mouseFimplications for psychiatric disorders such as schizophrenia and autism. Eur Neuropsychopharmacol 18: 712-716.
89. Wise RA (2008). Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res 14: 169-183.
90. Wolff AR, Bilkey DK (2008). Immune activation during mid-gestation disrupts sensorimotor gating in rat offspring. Behav Brain Res 190: 156-159.
91. Zemlan FP, Hirschowitz J, Garver DL (1986). Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients. Arch Gen Psychiatry 43: 1162-1167.
92. Zuckerman L, Rehavi M, Nachman R, Weiner I (2003). Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyper-function, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychophar-macology 28: 1778-1789.
93. Zuckerman L, Weiner I (2005). Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 39: 311-323.